Company intelligence / Profile preview
KaloCyte
Baltimore, Maryland, United Stateskalocyte.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
KaloCyte has demonstrated proof of concept, safety, and efficacy in animal models for ErythroMer. The company has had a successful pre-IND meeting with FDA and is preparing for IND-enabling studies[3].
- Therapeutic areas
- Hematology
- Modalities
- Artificial red blood cell substitute
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Blue Knight (collaboration between BARDA and Johnson & Johnson's JLABS)Scorpius Holdings, Inc.
Beyond the preview
Go deeper on KaloCyte.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KaloCyte.